AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 12
Study 19890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 12
Study 19890250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18327510 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 1288
Study 18327510 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work with baseline SBP > or = 140 mmHg and an additional increase
Number of subjects: 1288
Study 18327510 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1288
Study 18327510 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 1288
Study 18327510 — intervention group
Group type: COMPARATOR
Intervention: No exposure (day workers)
Number of subjects: 1288
Study 15724758 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with Atrisorb resorbable membrane
Number of subjects: 10
Study 15724758 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 10
Study 11394391 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with the basement membrane side against the root (AB)
Number of subjects: 10
Study 11394391 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) with the connective tissue side against the root (AC)
Number of subjects: 10
Study 11394391 — intervention group
Group type: COMPARATOR
Intervention: Both AB and AC sites
Number of subjects: 10
Study 11394391 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (AB and AC)
Number of subjects: 10
Study 9885088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling intervention delivered by the Cancer Information and Counseling Line (CICL) including 16 telephone outcalls over a 12-month period.
Number of subjects: 400
Study 9885088 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 400
Study 7993324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive techniques program for preventing depressive symptoms
Number of subjects: 142
Study 7993324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 2500068 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT-MMC therapy (400 or 600 mg/day of UFT, plus 6 or 8 mg/body of MMC intravenously weekly for three weeks, then triweekly after six weeks)
Number of subjects: 75
Study 2500068 — intervention group
Group type: COMPARATOR
Intervention: UFT-ACR therapy (400 or 600 mg/day of UFT, plus 20 mg/body of ACR intravenously for 5 serial days every three weeks)
Number of subjects: 75
Study 2500068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 7933495 — intervention group
Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion at 5, 10 ml.kg‐1.h‐1 for 3 hours
Number of subjects: 18
Study 7933495 — intervention group
Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion at 15 ml.kg‐1.h‐1 for 2 hours
Number of subjects: 18
Study 7933495 — intervention group
Group type: EXPERIMENTAL
Intervention: New intraoperative fluid infusion
Number of subjects: 18
Study 639574 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratolytic gel treatment
Number of subjects: 0
Study 30251137 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dry lab training prior to surgery
Number of subjects: 39
Study 30251137 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior training)
Number of subjects: 39
Study 28708072 — intervention group
Group type: EXPERIMENTAL
Intervention: CF fortified with 2 mg NaFeEDTA plus 3.8 mg FeFum for six days/week (n = 126)
Number of subjects: 378
Study 28708072 — intervention group
Group type: EXPERIMENTAL
Intervention: CF fortified with 2 mg NaFeEDTA and 3.8 mg FePP for six days/week (n = 127)
Number of subjects: 378
Study 28708072 — intervention group
Group type: COMPARATOR
Intervention: No food intervention (n = 125)
Number of subjects: 378
Study 25864858 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-gold nanoparticles (NP) in a bioengineered on-artery patch
Number of subjects: 180
Study 25864858 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-gold iron-bearing NP with targeted micro-bubbles and stem cells using a magnetic navigation system
Number of subjects: 180
Study 25864858 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 180
Study 24089379 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 0
Study 24089379 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 21777745 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical minithoracotomic LV lead implantation (Group 1)
Number of subjects: 40
Study 21777745 — intervention group
Group type: COMPARATOR
Intervention: Transvenous LV lead implantation (Group 2)
Number of subjects: 40
Study 19302516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-to-parent consultation
Number of subjects: 20
Study 19302516 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 20
Study 17505029 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood interferon-gamma ELISA (QuantiFERON-TB Gold [QFT-G])
Number of subjects: 144
Study 17505029 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma enzyme-linked immunospot assay (T SPOT.TB)
Number of subjects: 144
Study 17505029 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 144
Study 15452837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasterone 200 mg/day
Number of subjects: 381
Study 15452837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 11445487 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isoxsuprine hydrochloride (60 mg/day orally)
Number of subjects: 44
Study 11445487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9669262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 576
Study 7818725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 50 mg day‐1 for days 1-3; 3 x 100 mg day‐1 for days 4-7)
Number of subjects: 6
Study 7818725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3291444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 10
Study 3291444 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 10
Study 31981498 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients (n=99)
Number of subjects: 8935
Study 31981498 — intervention group
Group type: COMPARATOR
Intervention: Unscreened patients (n=516)
Number of subjects: 8935
Study 31556978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 9006
Study 31556978 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 9006
Study 28612453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity 4-week intervention including compassion, mindfulness, and acceptance practices
Number of subjects: 20
Study 28612453 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study 25773919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 10003
Study 25773919 — intervention group
Group type: COMPARATOR
Intervention: Functional testing (exercise electrocardiography, nuclear stress testing, or stress echocardiography)
Number of subjects: 10003
Study 25773919 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA
Number of subjects: 10003
Study 25773919 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study 23527561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (15 pmol kg(‐1) min(‐1) for 3 hours before and on day 2 after surgery)
Number of subjects: 24
Study 23527561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 24
Study 23527561 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 24
Study 21844318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg b.i.d.)
Number of subjects: 1164
Study 21844318 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg q.i.d.)
Number of subjects: 1164
Study 21844318 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1164
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic and psychotherapeutic treatments
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of self‐rated pretreatment suicidal ideation (Suicidal Ideation Questionnaire adapted for adolescents score >= 31)
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depressive symptoms (Reynolds Adolescent Depression Scale score >= 91)
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions‐Severity of Illness scale score
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions‐Improvement scale score
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific interpersonal stressors
Number of subjects: 439
Study 19552869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal events
Number of subjects: 439
Study 16955616 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel technique for microimplant placement
Number of subjects: 41
Study 16955616 — intervention group
Group type: COMPARATOR
Intervention: Established method (control technique)
Number of subjects: 41
Study 15700744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/silver sulfadiazine cream
Number of subjects: 0
Study 15700744 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream alone
Number of subjects: 0
Study 10802273 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix IUD
Number of subjects: 600
Study 10802273 — intervention group
Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 600
Study 9395681 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional research techniques
Number of subjects: 0
Study 9395681 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study 9395681 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative methodologies
Number of subjects: 0
Study 1312769 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP (mytomicin, ifosfamide, cisplatin)
Number of subjects: 0
Study 1312769 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (substituted for cisplatin in MIP)
Number of subjects: 0
Study 1312769 — intervention group
Group type: COMPARATOR
Intervention: VIP (vindesine, ifosfamide, cisplatin)
Number of subjects: 0
Study 3919352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum (2.0 mg)
Number of subjects: 193
Study 3919352 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 193
Study 3919352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum
Number of subjects: 193
Study 29374780 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression treatment (N=82)
Number of subjects: 153
Study 29374780 — intervention group
Group type: COMPARATOR
Intervention: Elevation (Control) (N=71)
Number of subjects: 153
Study 25667258 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour schedule
Number of subjects: 49
Study 25667258 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-hour schedule
Number of subjects: 49
Study 25667258 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour schedule
Number of subjects: 49
Study 24023027 — intervention group
Group type: EXPERIMENTAL
Intervention: FORE‐SIGHT® (Casmed, Branford, CT)
Number of subjects: 23
Study 24023027 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS® 5100C (Covidien, Boulder, CO)
Number of subjects: 23
Study 24023027 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRO‐200NX® (Hamamatsu Photonics, Hamamatsu City, Japan)
Number of subjects: 23
Study 24023027 — intervention group
Group type: EXPERIMENTAL
Intervention: EQUANOX® 7600 (3‐wavelength version)
Number of subjects: 23
Study 24023027 — intervention group
Group type: EXPERIMENTAL
Intervention: EQUANOX® 7600 (4‐wavelength version)
Number of subjects: 23
Study 21437317 — intervention group
Group type: EXPERIMENTAL
Intervention: Active after-sun (AS) lotion containing DNA-repair enzymes (photolyase from Anacystis nidulans and Micrococcus luteus extract with endonuclease activity)
Number of subjects: 14
Study 21437317 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 14
Study 21437317 — intervention group
Group type: COMPARATOR
Intervention: Untreated test fields
Number of subjects: 14
Study 21437317 — intervention group
Group type: COMPARATOR
Intervention: SPF30 sunscreen
Number of subjects: 14
Study 18242722 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-RSV01 (150mg, single dose and for five daily doses)
Number of subjects: 101
Study 18242722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 101
Study 16774662 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPE42 self-report instrument
Number of subjects: 765
Study 14515596 — intervention group
Group type: COMPARATOR
Intervention: Whitening strips (6% hydrogen peroxide)
Number of subjects: 48
Study 14515596 — intervention group
Group type: EXPERIMENTAL
Intervention: Paint-on gel (18% carbamide peroxide)
Number of subjects: 48
Study 14515596 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening dentifrice (no peroxide)
Number of subjects: 48
Study 10028214 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait Anger scale
Number of subjects: 65
Study 10028214 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report anger scales
Number of subjects: 65
Study 7722912 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 7722912 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 7722912 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen vehicle
Number of subjects: 0
Study 2029499 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered boiled coffee (lipid content, 1.0 g/l)
Number of subjects: 64
Study 2029499 — intervention group
Group type: COMPARATOR
Intervention: Boiled and filtered coffee (0.02 g lipid/l)
Number of subjects: 64
Study 2029499 — intervention group
Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 64
Study 6268783 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmogen (piperazine oestrone sulphate)
Number of subjects: 55
Study 6268783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31208770 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening the lung strategy ventilation
Number of subjects: 66
Study 31208770 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilated as ARDS net)
Number of subjects: 66
Study 28246175 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA) plus standard care
Number of subjects: 4146
Study 28246175 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4146
Study 26088043 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and education provision (WEP) group
Number of subjects: 240
Study 26088043 — intervention group
Group type: COMPARATOR
Intervention: Education provision (EP) group
Number of subjects: 240
Study 23828615 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 48
Study 23828615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22810046 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional interactivity in eHealth application
Number of subjects: 165
Study 19409693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 581
Study 19409693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 581
Study 19409693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 581
Study 19409693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 581
Study 19409693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581
Study 19409693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (all doses)
Number of subjects: 581
Study 17103169 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Rituximab 375 mg/m² with intensified salvage chemotherapy)
Number of subjects: 67
Study 17103169 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (without Rituximab)
Number of subjects: 67
Study 17103169 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 67
Study 17103169 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 67
Study 15188945 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 102
Study 15188945 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 102
Study 11384787 — intervention group
Group type: EXPERIMENTAL
Intervention: Net health benefit analysis
Number of subjects: 0
Study 11384787 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying willingness-to-pay values
Number of subjects: 0
Study 9699400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector applied before band cementation with glass ionomer cement
Number of subjects: 18
Study 9699400 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement without Fluor Protector (control group)
Number of subjects: 18
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-shaped wrist
Number of subjects: 143
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Abductor pollicis brevis weakness
Number of subjects: 143
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve hypesthesia
Number of subjects: 143
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalen sign
Number of subjects: 143
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve compression sign
Number of subjects: 143
Study 9431262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffmann-Tinel sign
Number of subjects: 143
Study 1822438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg BID
Number of subjects: 10
Study 1822438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6813485 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 39
Study 6813485 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate
Number of subjects: 39
Study 6813485 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 39
Study 31877062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard shoes
Number of subjects: 848
Study 31877062 — intervention group
Group type: COMPARATOR
Intervention: Soft shoes
Number of subjects: 848
Study 30682333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation (seven daily doses)
Number of subjects: 76
Study 30682333 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 76
Study 30682333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation
Number of subjects: 76
Study 26763612 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal saliva substitute (chamomile and linseed)
Number of subjects: 74
Study 26763612 — intervention group
Group type: COMPARATOR
Intervention: Conventional saliva substitute (carboxymethyl cellulose)
Number of subjects: 74
Study 25596344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 25596344 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23733668 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane + dexmedetomidine (group DISO)
Number of subjects: 60
Study 23733668 — intervention group
Group type: COMPARATOR
Intervention: isoflurane + saline (group NISO)
Number of subjects: 60
Study 21708030 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR below 60 ml/min/1.73 m²
Number of subjects: 6653
Study 21708030 — intervention group
Group type: COMPARATOR
Intervention: eGFR normal
Number of subjects: 6653
Study 21708030 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 6653
Study 21708030 — intervention group
Group type: EXPERIMENTAL
Intervention: se-creatinine
Number of subjects: 6653
Study 17591648 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA (Arachidonic acid 240 mg/day, Docosahexaenoic acid 240 mg/day)
Number of subjects: 28
Study 17591648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16548864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 2 microg/kg of clonidine
Number of subjects: 60
Study 12948063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 16
Study 12948063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10989853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA) with Normal curved tracheal tube
Number of subjects: 240
Study 10989853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA) with Reverse curved tracheal tube
Number of subjects: 240
Study 8891657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud display (parallax and expansion congruent)
Number of subjects: 0
Study 8891657 — intervention group
Group type: EXPERIMENTAL
Intervention: Other displays (hallway, side walls, ground surface, wall, wall with central hole, hall farther, wall farther)
Number of subjects: 0
Study 1857725 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g as Ca/day)
Number of subjects: 12
Study 1857725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calcium diet (163 +/- 1 mg/day)
Number of subjects: 12
Study 1857725 — intervention group
Group type: COMPARATOR
Intervention: Normal Calcium intake (536 +/- 2 mg/day)
Number of subjects: 12